PHAXIAM Therapeutics
Jerome BAILLY is currently the Directeur Général Délégué, Chief Quality & Pharmaceutical Officer, and Pharmacien Responsable at Phaxiam Therapeutics, where he manages and oversees global quality and pharmaceutical operations. With a background in engineering and pharmaceutical sciences, he has previously held key roles at ERYTECH Pharma, Laboratoire Aguettant, and Pierre Fabre Group, focusing on quality control, pharmaceutical operations, and industrial transfer validation. Jerome is a highly experienced professional with expertise in strategic organization, batch release, supply chain management, and logistics optimization in the pharmaceutical industry.
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.